NO20074065L - Farmakogenomiske markorer for prognose av faste tumorer - Google Patents

Farmakogenomiske markorer for prognose av faste tumorer

Info

Publication number
NO20074065L
NO20074065L NO20074065A NO20074065A NO20074065L NO 20074065 L NO20074065 L NO 20074065L NO 20074065 A NO20074065 A NO 20074065A NO 20074065 A NO20074065 A NO 20074065A NO 20074065 L NO20074065 L NO 20074065L
Authority
NO
Norway
Prior art keywords
prognosis
patients
solid tumors
gene
cci
Prior art date
Application number
NO20074065A
Other languages
English (en)
Norwegian (no)
Inventor
Andrew J Dorner
Natalie Constance Twine
William L Trepicchio
Donna K Slonim
Frederick Immermann
Michael E Burczynski
Andrew Strahs
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20074065L publication Critical patent/NO20074065L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20074065A 2005-02-18 2007-08-07 Farmakogenomiske markorer for prognose av faste tumorer NO20074065L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65408205P 2005-02-18 2005-02-18
PCT/US2006/005772 WO2006089185A2 (en) 2005-02-18 2006-02-17 Pharmacogenomic markers for prognosis of solid tumors

Publications (1)

Publication Number Publication Date
NO20074065L true NO20074065L (no) 2007-11-14

Family

ID=36649050

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074065A NO20074065L (no) 2005-02-18 2007-08-07 Farmakogenomiske markorer for prognose av faste tumorer

Country Status (15)

Country Link
US (1) US20090061423A1 (pt)
EP (1) EP1849007A2 (pt)
JP (1) JP2008529554A (pt)
KR (1) KR20070115891A (pt)
CN (1) CN101120255A (pt)
AU (1) AU2006214078A1 (pt)
BR (1) BRPI0608429A2 (pt)
CA (1) CA2598393A1 (pt)
CR (1) CR9298A (pt)
IL (1) IL185206A0 (pt)
MX (1) MX2007010001A (pt)
NO (1) NO20074065L (pt)
RU (1) RU2007129864A (pt)
WO (1) WO2006089185A2 (pt)
ZA (1) ZA200706919B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5435529B2 (ja) * 2005-09-02 2014-03-05 東レ株式会社 腎ガン診断、腎ガン患者予後予測のための組成物および方法
WO2008128043A2 (en) * 2007-04-11 2008-10-23 The General Hospital Corporation Diagnostic and prognostic methods for renal cell carcinoma
ES3027507T3 (en) 2010-01-11 2025-06-16 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
AU2015202116B2 (en) * 2010-01-11 2017-06-08 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
CA2903878C (en) 2013-05-30 2020-10-27 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
JP6427750B2 (ja) * 2013-10-02 2018-11-28 コニカミノルタ株式会社 Ｃｘｃｌ１、ならびにｓｍｏｘおよび／またはｉｄ１の発現量に基づく肺癌患者の予後を判定するためのデータ収集方法およびキット
US20180044736A1 (en) * 2015-02-03 2018-02-15 Cedars-Sinai Medical Center Biomarker based prognostic model for predicting overall survival in patients with metastatic clear cell kidney cancer
US20180100859A1 (en) * 2015-03-24 2018-04-12 Eutropics Pharmaceuticals, Inc. Surrogate functional biomarker for solid tumor cancer
CN111537424B (zh) * 2020-04-26 2022-10-28 北京市神经外科研究所 基于外周血细胞评估脊髓胶质瘤患者预后性的系统
CN111640518A (zh) * 2020-06-02 2020-09-08 山东大学齐鲁医院 一种宫颈癌术后生存预测方法、系统、设备及介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020076735A1 (en) * 1998-09-25 2002-06-20 Williams Lewis T. Diagnostic and therapeutic methods using molecules differentially expressed in cancer cells
JP3944996B2 (ja) * 1998-03-05 2007-07-18 株式会社日立製作所 Ｄｎａプローブアレー
EP1356114A2 (en) * 2001-01-31 2003-10-29 Whitehead Institute For Biomedical Research Brain tumor diagnosis and outcome prediction
US7622260B2 (en) * 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
AU2003298689A1 (en) * 2002-11-21 2004-06-18 Wyeth Methods for diagnosing rcc and other solid tumors

Also Published As

Publication number Publication date
IL185206A0 (en) 2008-01-06
WO2006089185A2 (en) 2006-08-24
JP2008529554A (ja) 2008-08-07
CR9298A (es) 2007-11-23
EP1849007A2 (en) 2007-10-31
WO2006089185A8 (en) 2007-09-27
BRPI0608429A2 (pt) 2009-12-29
RU2007129864A (ru) 2009-03-27
ZA200706919B (en) 2008-06-25
MX2007010001A (es) 2007-09-27
CN101120255A (zh) 2008-02-06
WO2006089185A3 (en) 2006-09-28
US20090061423A1 (en) 2009-03-05
KR20070115891A (ko) 2007-12-06
CA2598393A1 (en) 2006-08-24
AU2006214078A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
Dotan et al. Adult genitourinary sarcoma: the 25-year Memorial Sloan-Kettering experience
WO2019195268A3 (en) Methylation markers and targeted methylation probe panels
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
HK1214615A1 (zh) 與賴氨醯氧化酶樣蛋白2(loxl2)相關的治療和診斷方法
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
BRPI0718322A2 (pt) Métodos para diagnosticar uma suscetibilidade para câncer em um indivíduo humano, para identificar um marcador para o uso na avaliação da suscetibilidade para câncer, para genotipar uma amostra de ácido nucléico, para avaliar um inidivíduo quanto a probabilidade de resposta a um agente terapêutico, para predizer o prognóstico e para monitorar o progresso de um tratamento de um indivíduo, kit para avaliar a suscetibilidade para câncer em um indivíduo, uso de uma sonda de oligonucleotídeo, meio legível por computador, e, aparelho para determinar um indicador genético para câncer em um indivíduo.
WO2011027310A8 (en) Novel tumor markers
WO2008128169A8 (en) Sparc and methods of use thereof
MX389730B (es) Extinguidor que contiene nanomaterial conjugado con polimero soluble en agua y su uso.
WO2011027308A8 (en) Novel tumor markers
ECSP088835A (es) Terapia combinatoria que involucra antagonistas de alfa5beta1
EP4435112A3 (en) Compositions and methods for screening solid tumors
NI200700126A (es) Metodos y sistemas para el pronostico y tratamiento de tumores solidos
CR9298A (es) Marcadores farmacogenomicos para el pronostico de tumores solidos
ATE492651T1 (de) Moesin, caveolin 1 und yes-assoziiertes protein 1 als prädiktive marker der reaktion auf dasatinib bei brustkrebs
Itchins et al. Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre
Puente et al. Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma
MX2015013172A (es) Metodos para determinar el pronostico de cancer colorrectal.
WO2011027311A3 (en) Novel tumor markers
BRPI0607016A2 (pt) marcadores polipeptìdicos para o diagnóstico de cáncer de próstata
WO2007023191A3 (de) Polypeptidmarker zur diagnose von blasenkrebs
Demircioglu et al. Lymph node ratio assessment of brain metastasis in early breast cancer cases
Gaya et al. Is there a limit for the laparoscopic approach of a retroperitoneal residual mass postchemotherapy?
WO2019103421A3 (ko) 유전자의 cpg 메틸화 변화를 이용한 간암의 예후 또는 위험도를 평가하는 방법
UK Non-Hodgkin's Lymphoma: diagnosis and management

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application